AC Immune SA (ACIU)'s Financial Results Comparing With Novus Therapeutics Inc. (NASDAQ:NVUS) - EN Digest

As Biotechnology businesses, AC Immune SA (NASDAQ:ACIU) and Novus Therapeutics Inc. (NASDAQ:NVUS), are affected by compare. This especially applies to their risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AC Immune SA N/A 0.00 N/A -0.54 0.00
Novus Therapeutics Inc. N/A 0.00 11.60M -1.37 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of AC Immune SA and Novus Therapeutics Inc.

Profitability

Table 2 provides the return on assets, net margins and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
AC Immune SA 0.00% -25.2% -22.4%
Novus Therapeutics Inc. 0.00% -55.5% -51.7%

Liquidity

19.2 and 19.2 are the respective Current Ratio and a Quick Ratio of AC Immune SA. Its rival Novus Therapeutics Inc.’s Current and Quick Ratios are 10.7 and 10.7 respectively. AC Immune SA has a better chance of clearing its pay short and long-term debts than Novus Therapeutics Inc.

Institutional & Insider Ownership

Institutional investors owned 30.3% of AC Immune SA shares and 52.9% of Novus Therapeutics Inc. shares. AC Immune SA’s share owned by insiders are 51.48%. On the other hand, insiders owned about 0.8% of Novus Therapeutics Inc.’s shares.

Performance

Here are the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
AC Immune SA -1.53% 24.15% 37.22% 11.28% -8.75% -14.45%
Novus Therapeutics Inc. -20.46% -33.01% -39.07% -56.67% -36.7% -32.02%

For the past year AC Immune SA was less bearish than Novus Therapeutics Inc.

Summary

AC Immune SA beats on 6 of the 6 factors Novus Therapeutics Inc.

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms generates antibodies and small molecules that selectively bind to misfolded proteins to address neurodegenerative indications, such as AlzheimerÂ’s (AD), ParkinsonÂ’s, down syndrome, and glaucoma diseases. The companyÂ’s lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase 3 clinical studies. It also engages in developing ACI-24, a vaccine candidate that is in a combined Phase 1/2a clinical study for AD; and ACI-35, a vaccine candidate against phosphorylated pathological tau and is currently in Phase 1b clinical testing in patients with mild to moderate AD. In addition, the company develops PET ligands that are tracers to target tau and alpha-synuclein aggregates. It has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Piramal Imaging; and Biogen International GmbH. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.

Novus Therapeutics, Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of ear, nose, and throat products. Its lead product is a nasally-administered combination drug product (OP-02) intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD) conditions. The company also has a foam-based drug delivery technology platform (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities. It is developing a foam-based combination drug-product to the external ear canal that is an improved treatment option for acute otitis externa. The company is headquartered in Irvine, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



http://bit.ly/2DK6Jt6

Comments

Popular posts from this blog

Uveitis Eye Inflammation Causes, Symptoms & Treatment

Robert Zakar gives back to community

Goopy Eyes: Causes and Treatment